Does Repatha Help with Triglycerides?
Repatha (evolocumab) is NOT indicated for treating hypertriglyceridemia—it primarily lowers LDL cholesterol by approximately 60% and has only modest effects on triglycerides. 1, 2
Primary Mechanism and Lipid Effects
Repatha works by blocking PCSK9 protein, which increases LDL receptor availability to clear LDL cholesterol from the bloodstream. 3 While this mechanism powerfully reduces LDL-C by 50-65%, the impact on triglycerides is minimal and not clinically significant for treating hypertriglyceridemia. 1
The drug's lipid profile effects include:
- LDL cholesterol reduction: 50-65% 1
- Lipoprotein(a) reduction: up to 25% 1
- Triglyceride effects: Not a primary target or significant benefit 4, 1
Guideline-Recommended Treatments for Hypertriglyceridemia
For severe hypertriglyceridemia (≥500 mg/dL), use fibric acid derivatives and/or fish oil to reduce pancreatitis risk, not PCSK9 inhibitors. 4
For moderate hypertriglyceridemia (135-499 mg/dL) in patients with ASCVD on statins with controlled LDL-C, consider icosapent ethyl (not Repatha) to reduce cardiovascular risk. 4
The American Diabetes Association guidelines specifically recommend addressing hypertriglyceridemia through:
- Lifestyle modifications (weight loss, alcohol abstinence) 4
- Treatment of secondary causes (diabetes, hypothyroidism, kidney disease) 4
- Fibrates for severe cases (≥500 mg/dL) 4
- Icosapent ethyl for moderate elevation with residual cardiovascular risk 4
When Repatha IS Appropriate
Repatha should be reserved for patients with:
- Established ASCVD with LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe 5, 3
- Heterozygous familial hypercholesterolemia with LDL-C ≥100 mg/dL despite maximal therapy 5
- Multiple major ASCVD events or very high cardiovascular risk 5
The FOURIER trial demonstrated that evolocumab reduces major cardiovascular events by 15% and the composite of cardiovascular death, MI, or stroke by 20% in high-risk patients—but this benefit derives from LDL-C lowering, not triglyceride reduction. 3
Special Population: Familial Dysbetalipoproteinemia
One notable exception exists: In patients with familial dysbetalipoproteinemia (Type III hyperlipidemia) who are resistant or intolerant to statins and fibrates, evolocumab reduced VLDL-cholesterol and cholesterol-rich remnant particles throughout the density spectrum. 6 However, this represents a rare genetic disorder with abnormal triglyceride-rich lipoproteins, not typical hypertriglyceridemia. 6
Clinical Bottom Line
Do not prescribe Repatha for hypertriglyceridemia. Use fibrates, fish oil, or icosapent ethyl depending on severity and clinical context. 4, 1 Reserve Repatha for its FDA-approved indication: reducing cardiovascular risk in patients with elevated LDL cholesterol despite maximal statin therapy, where its powerful LDL-lowering effect (not triglyceride effect) drives clinical benefit. 5, 3